Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas

American Journal of Surgical Pathology

Volumn 36, Issue 8, 2012, Pages 1186-1193

  Hobbs, Jonathan ^a   Nikiforova, Marina N ^b   Fardo, David W ^a   Bortoluzzi, Stephanie ^b   Cieply, Kathleen ^b   Hamilton, Ronald L ^b   Horbinski, Craig ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

amplification; EGFR; glioblastoma; temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; DRUG RESISTANCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO ONCOGENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863813631     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182518e12     Document Type: Article

References (33)

1. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol. 2004;63:700-707. (Pubitemid 38891086)
2. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10:228-233. (Pubitemid 38114184)
3. Benito R, Gil-Benso R, Quilis V, et al. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Neuropathology. 2009;30:392-400.
4. Biernat W, Tohma Y, Yonekawa Y, et al. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 1997;94:303-309. (Pubitemid 27450108)
5. Birkbak NJ, Eklund AC, Li Q, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 2011;71:3447-3452.
6. Brandes AA, Franceschi E, Tosoni A, et al. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res. 2008;14:957-960. (Pubitemid 351302539)
7. Chakravarti A, Chakladar A, Delaney MA, et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002;62:4307-4315. (Pubitemid 34827287)
8. Eley GD, Reiter JL, Pandita A, et al. A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neuro Oncol. 2002;4:86-94. (Pubitemid 34285062)
9. Gibaud A, Vogt N, Hadj-Hamou NS, et al. Extrachromosomal amplification mechanisms in a glioma with amplified sequences from multiple chromosome loci. Hum Mol Genet. 2010;19:1276-1285.
10. Hatanpaa KJ, Burma S, Zhao D, et al. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12:675-684.
11. Horbinski C, Hamilton RL, Nikiforov Y, et al. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol. 2010;119:641-649.
12. Horbinski C, Hobbs J, Cieply K, et al. EGFR expression stratifies oligodendroglioma behavior. Am J Pathol. 2011;179:1638-1644.
13. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer. 2006;106:2218-2223. (Pubitemid 43673244)
14. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age 50 years. Cancer. 2005;104:825-832 (Pubitemid 41113684)
15. Layfield LJ, Willmore C, Tripp S, et al. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol. 2006;14:91-96.
16. Li L, Dutra A, Pak E, et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009;11:9-21.
17. Liu L, Backlund LM, Nilsson BR, et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med. 2005;83: 917-926. (Pubitemid 41598692)
18. Lopez-Gines C, Gil-Benso R, Ferrer-Luna R, et al. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Mod Pathol. 2010; 23:856-865.
19. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumors of the Central Nervous System. Lyon: IARC; 2007.
20. Mazzoleni S, Politi LS, Pala M, et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 2010;70:7500-7513.
21. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024. (Pubitemid 41609094)
22. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996;56:5079-5086. (Pubitemid 26374452)
23. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64: 6892-6899. (Pubitemid 39330996)
24. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479-489. (Pubitemid 40781150)
25. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100:2235-2241.
26. Park S, James CD. Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. Cancer Res. 2003;63:723-727. (Pubitemid 36158153)
27. Park S, James CD. ECop (EGFR-coamplified and overexpressed protein), a novel protein, regulates NF-kappaB transcriptional activity and associated apoptotic response in an IkappaBalphadependent manner. Oncogene. 2005;24:2495-2502. (Pubitemid 40593040)
28. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579-584.
29. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962-6970. (Pubitemid 37322983)
30. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93: 1246-1256. (Pubitemid 32816199)
31. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of realtime methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008;10:332-337. (Pubitemid 352019119)
32. Vogt N, Lefevre SH, Apiou F, et al. Molecular structure of doubleminute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci USA. 2004;101:11368-11373. (Pubitemid 39038353)
33. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011;20:143-157.